01.002 RWE KR June 2022 H 08-07-2022

RWE helps accelerate oncology drug development timelines by 1-3 years

  • Key insights from the research included: engage the FDA early to confirm appropriate data sources; select appropriate data sources to ensure real-world data are high quality and fit for purpose
  • “Moreover, we found that inclusion of RWE helped accelerate oncology drug development timelines by 1–3 years. That directly relates to getting urgently needed treatments into the hands of patients with difficult-to-treat cancers.“                                                                                                                                                                                                                                                                        Maral DerSakissian, Analysis Group Vice President
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at